This result confirmed the higher immunogenicity of colonic tumour cells with MMR gene deficiency and suggested a possible clinical use of oxidative stress to enhance immune response to CRC besides the existing immunotherapy trial [35]. This evidence concerns the gene MRC1 and digestive system neoplasm.